Prothena | PRTA - Loan Capital


Prothena reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
ALKERMES USD 1.48B 1.2B Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Immunic USD 0 0 Jun/2024
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
MacroGenics USD 70M 256K Dec/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xoma USD 94.38M 7.82M Sep/2025